Literature DB >> 19670076

Final results of a long-term, clinical follow-up in fatty liver patients.

Sanne Dam-Larsen1, Ulrik Becker, Maria-Benedicte Franzmann, Klaus Larsen, Per Christoffersen, Flemming Bendtsen.   

Abstract

OBJECTIVE: There is increasing focus on non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to conduct a long-term clinical follow-up of patients with biopsy-confirmed fatty liver without inflammation or significant fibrosis (pure fatty liver), to analyse for potential risk factors at the time of index liver biopsy important for survival and the development of cirrhosis and to describe the causes of death.
MATERIAL AND METHODS: Patients were linked through their personal identification number to the Danish National Registry of Patients and the Register of Causes of Death. All admissions, discharge diagnoses and causes of death during follow-up were collected. All surviving patients were invited to a clinical follow-up.
RESULTS: The follow-up period was 20.4 and 21.0 years, respectively, for the NAFLD and alcoholic fatty liver disease (AFLD) groups. Two NAFLD patients (1.2%) developed cirrhosis during the follow-up period versus 54 (22%) AFLD patients. Sixty-four percent of 178 surviving patients out of an original cohort of 417 patients attended the clinical follow-up. In NAFLD patients, none of the risk factors studied was significant in relation to the risk of death. Patients with AFLD died primarily from cirrhosis and other alcohol-related disorders, whereas in patients with NAFLD the main causes of death were cardiovascular disease and cancer.
CONCLUSIONS: For patients with pure non-alcoholic fatty liver, survival was good and independent of the histological, clinical and biochemical characteristics at the time of biopsy; the main causes of death were cardiovascular disease and cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19670076     DOI: 10.1080/00365520903171284

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  58 in total

1.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

Review 2.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Clinical trials: Trial design in NASH--realities and challenges.

Authors:  Paul Angulo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-05       Impact factor: 46.802

4.  The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease.

Authors:  Phunchai Charatcharoenwitthaya; Keith D Lindor; Paul Angulo
Journal:  Dig Dis Sci       Date:  2012-02-29       Impact factor: 3.199

Review 5.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

Review 7.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

8.  Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.

Authors:  Raj Vuppalanchi; Mohammad S Siddiqui; Mark L Van Natta; Erin Hallinan; Danielle Brandman; Kris Kowdley; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivas Dasarathy; Manal Abdelmalek; Edward Doo; James A Tonascia; David E Kleiner; Arun J Sanyal; Naga Chalasani
Journal:  Hepatology       Date:  2017-11-29       Impact factor: 17.425

Review 9.  Effects of resveratrol and other polyphenols in hepatic steatosis.

Authors:  Leixuri Aguirre; Maria Puy Portillo; Elizabeth Hijona; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?

Authors:  Francesco Sofi; Alessandro Casini
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.